Senseonics stock gets Eversense 365-iLet launch
Published on 11/17/2026 at 22:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSIntegration Expands Diabetes Technology Options
- Senseonics and Beta Bionics launched the commercial integration of Eversense 365 with the iLet Bionic Pancreas on November 16, 2026.
- The companies plan to integrate Eversense 365 with Beta Bionics' Mint tubeless patch pump in the future.
Senseonics Holdings and Beta Bionics announced the commercial launch of the iLet Bionic Pancreas integrated with Senseonics' Eversense 365 continuous glucose monitoring system on November 16, 2026. The Senseonics release said the launch fulfills the companies' previously announced fourth-quarter 2026 timeline.
Broader Automated Insulin Delivery Choice
Eversense 365 is designed to provide glucose monitoring for up to one year with a single implanted sensor. The iLet system uses continuous glucose monitoring data and an adaptive algorithm to determine and deliver insulin doses.
Senseonics said the integration gives Eversense 365 users another automated insulin-delivery option. The companies also plan to integrate Eversense 365 with Mint, Beta Bionics' tubeless patch pump, in the future.
Latest Senseonics Stock Quote
Senseonics stock traded at 9.38 euros on Lang & Schwarz at 22:56 CET on Tuesday, November 17, 2026.
Senseonics Holdings at a Glance
- Company: Senseonics Holdings, Inc.
- Ticker: SENS
- Primary exchange: Nasdaq
- Quote: 9.38 euros on Lang & Schwarz, November 17, 2026, 22:56 CET
Nasdaq-listed medical technology companies remain part of the broader Nasdaq Composite market environment.
